SecBot SecBot
SECBOTREPLAY Home › Report › PTGX

PTGX · Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on…

Protagonist Therapeutics, Inc · CLUSTER filed May 7, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed May 7, 2026 at 20:00 ET

Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director Bryan Giraudo on May 8, creating a two-insider sell cluster totaling $8.11M. The sales occurred just 9 days after a massive Q1 earnings beat (revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus) driven by milestone payments from ICOTYDE FDA approval and the rusfertide opt-out. While the earnings beat is clearly positive, the CEO's large open-market sale immediately after exercising options at $21.58/share (realizing ~$7.5M profit) is a routine cashless exercise pattern, the stock is up ~364% from the option strike, and the sale represents only ~0.12% of the $6.7B market cap, falling below the 0.5% materiality threshold.

  • CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026, after exercising options at $21.58/share
  • Director Bryan Giraudo sold 6,000 shares at $100.00 for $600K on May 8, 2026
  • Total cluster value: $8.11M, representing ~0.12% of PTGX's $6.7B market cap
  • Sales occurred 9 days after Q1 2026 earnings beat: revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access